Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Target Recruit Count
- 234
- Registration Number
- NCT06148649
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China
A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects
Phase 1
Completed
- Conditions
- T2DM (Type 2 Diabetes Mellitus)ObesityHealthy Subjects
- Interventions
- Drug: HEC88473 injectionDrug: Placebo
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT05943886
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
Phase 1
Completed
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: HEC88473 injectionDrug: Placebo
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04829123
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, Australia
© Copyright 2025. All Rights Reserved by MedPath